araag2/HINT huggingface dataset:
Clinical trial NCT00541697 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: mk0653a, ezetimibe (+) simvastatin / duration of treatment: 6 weeks, comparator: atorvastatin / duration of treatment: 6 weeks
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Currently being treated with Atorvastatin 10 mg for at least 6 weeks

          -  Have Type 2 Diabetes

          -  Weight must be stable for more than 6 weeks before entering the study

        Exclusion Criteria:

          -  Consume more than 14 alcoholic drinks per week.

          -  Pregnant or lactating

          -  Have taken another investigation drug within 3 months of starting this study

          -  History of congestive heart failure, heart attack, coronary artery bypass surgery

          -  Uncontrolled high blood pressure

          -  HIV positive

          -  History of cancer in the last 5 years
Clinical trial NCT00363415 (phase 3, status: completed)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, etoposide, carboplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of extensive stage small cell lung cancer (SCLC)

          -  Capable of self-care but may be unable to carry out any work activities.

          -  No prior anticancer therapy for SCLC

        Exclusion Criteria:

          -  have previously participated in a study involving pemetrexed

          -  have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication
Clinical trial NCT00372697 (phase 3, status: completed)
Conditions: acromegaly
ICD codes: E22.0
Drugs: octreotide acetate 30 mg suspension
SMILES: [H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1=CC=CC=C1)[C@@H](C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Written voluntary informed consent.

          -  Patients with biochemically documented active acromegaly who are currently receiving
             somatostatin-analogues in a conventional treatment regimen (octreotide up to 30 mg/28
             days; lanreotide up to 120 mg/28 days) for at least 6 months.

          -  Patients with uncontrolled disease defined as patients with a decrease of baseline
             levels of growth hormone (GH) ≥ 50% during treatment with somatostatin-analogues in a
             conventional regimen (sandostatin up to 30 mg/28 days; lanreotide up to 120 mg/28
             days) for at least 6 months.

          -  Baseline (mean of 3 samples) GH level > 2 µg/L.

          -  Insulin-like Growth Factor I (IGF-I) levels above the upper limits of normal for age
             and gender.

        Other protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT00326027 (phase 3, status: completed)
Conditions: gastroesophageal reflux
ICD codes: K21.9, K21.00, K21.01
Drugs: pantoprazole
SMILES: COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1
Eligibility criteria:

        Main Inclusion Criteria:

          -  Written informed consent

          -  Inpatients (hospitalization during the entire study period is mandatory)

          -  Symptomatic (heartburn, acid regurgitation or dysphagia for at least 1 day since
             admission to the hospital) non-erosive reflux disease (NERD) or erosive
             gastroesophageal reflux disease (GERD, LA Grade A-D)

        Main Exclusion Criteria:

          -  Known Zollinger-Ellison syndrome or other gastric hypersecretory condition

          -  Previous acid-lowering surgery or other surgery of the esophagus and/or upper
             gastrointestinal tract (exception: polypectomy and cholecystectomy)

          -  On initial endoscopy, presence of obstructive esophageal strictures, Schatzki's ring,
             esophageal diverticula, esophageal varices, achalasia or Barrett's esophagus with
             known high-grade dysplasia or longer than 3 cm

          -  Acute peptic ulcer and/or ulcer complications

          -  Pyloric stenosis

          -  Known inflammatory bowel diseases
Clinical trial NCT00191646 (phase 3, status: completed)
Conditions: genital neoplasms, female, fallopian tube neoplasms, ovarian neoplasms, pelvic neoplasms, peritoneal neoplasms
ICD codes: C57.9, D28.9, C57.7, D28.7, C57.8, D39.9, D39.8, C57.00, C57.01, C57.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C41.4, D16.8, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: gemcitabine, paclitaxel, carboplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Patients with a histologic diagnosis of primary peritoneal carcinoma, epithelial
             ovarian carcinoma or fallopian tube carcinoma Stage IC, II, III or IV.

          -  All patients must have had surgery for fallopian, ovarian or peritoneal carcinoma to
             establish the diagnosis and have tissue available for histologic evaluation and
             confirmation of organ of origin.

          -  Patients must be enrolled no more than twelve weeks postoperatively.

          -  Patients must be willing to receive their chemotherapy drugs intravenously, as
             intraperitoneal therapy is not part of this trial.

        Key Exclusion Criteria:

          -  Patients with a current diagnosis of epithelial ovarian tumor of low malignant
             potential (Borderline carcinomas) are not eligible.

          -  Patients who have received prior radiotherapy to any portion of the abdominal cavity
             or pelvis are excluded

          -  Patients who have received prior chemotherapy for any abdominal or pelvic tumor are
             excluded

          -  With the exception of non-melanoma skin cancer and other specific malignancies
             patients who had (or have) any evidence of the other cancer present within the last 5
             years or whose previous cancer treatment contraindicates this protocol therapy are
             excluded.
Clinical trial NCT00051259 (phase 3, status: completed)
Conditions: major depressive disorder (mdd)
ICD codes: F25.1, F32.89, F33.8, F33.0, F33.1, F33.9, F32.0
Drugs: extended-release bupropion hydrochloride
SMILES: CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Primary diagnosis of Major Depressive Disorder (MDD) with current duration lasting 12
             weeks but no greater than 2 years.

          -  Subjects must engage in sexual activity that leads to orgasm at least once every two
             weeks.

          -  Subject must have normal orgasmic function and be willing to discuss with
             investigator.

        Exclusion Criteria:

          -  Subjects that have arousal or orgasm dysfunction.

          -  Has previously failed to respond to two adequate trials of antidepressants in past 2
             years.

          -  Subject has other unstable medical disorders.

          -  Subject has a positive urine test for illicit drug use at screening.
Clinical trial NCT00367614 (phase 3, status: completed)
Conditions: gastroesophageal reflux
ICD codes: K21.9, K21.00, K21.01
Drugs: pantoprazole
SMILES: COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  12-16 years old

          -  clinical diagnosis of GERD

          -  ability to swallow tablets

        Exclusion Criteria:

          -  GI or malabsorption disorders

          -  chronic use of warfarin

          -  positive pregnancy test
Clinical trial NCT00104676 (phase 3, status: active, not recruiting)
Conditions: extragonadal germ cell tumor, teratoma, testicular germ cell tumor
ICD codes: E29.0, E29.1, E29.8, E29.9, E89.5, N50.811, N50.812
Drugs: cisplatin, etoposide, ifosfamide, oxaliplatin, paclitaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of non-seminomatous germ cell tumors (NSGCT) as evidenced by 1 of the
             following criteria:

               -  Histologically confirmed NSGCT

               -  Clinical evidence of disease AND high serum human chorionic gonadotropin (HCG) or
                  alpha-fetoprotein (AFP) levels

          -  Clinical stage II-III disease (disseminated disease)

          -  Testicular, retroperitoneal, or mediastinal primary site

          -  Poor prognosis disease, meeting 1 of the following criteria:

               -  Mediastinal primary site

               -  Non-pulmonary visceral metastases

               -  One of the following lab values:

                    -  HCG > 50,000 UI/L

                    -  AFP > 10,000 ng/mL

                    -  Lactate dehydrogenase > 10 times upper limit of normal (ULN)

        PATIENT CHARACTERISTICS:

        Age

          -  Over 16

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute granulocyte count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Bilirubin ≤ 1.5 times ULN

        Renal

          -  Creatinine clearance > 60 mL/min

        Other

          -  No other prior malignancy except basal cell skin cancer

          -  No HIV positivity

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
Clinical trial NCT01242202 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ipragliflozin, alpha glucosidase inhibitor
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetic patients receiving with α-glucosidase inhibitor mono-therapy for at
             least 4 weeks

          -  HbA1c value between 6.5 and 9.5%

          -  Body Mass Index (BMI) 20.0 - 45.0 kg/m2

        Exclusion Criteria:

          -  Type 1 diabetes mellitus patients

          -  Serum creatinine > upper limit of normal

          -  Proteinuria (albumin/creatinine ratio > 300mg/g)

          -  Dysuria and/or urinary tract infection, genital infection

          -  Significant renal, hepatic or cardiovascular diseases

          -  Severe gastrointestinal diseases
Clinical trial NCT00544232 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: epirubicin, paclitaxel, cyclophosphamide, methotrexate, 5 fu, darbepoetin alfa, epirubicin, cyclophosphamide, paclitaxel, dabepoetin alfa
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed breast cancer: at least three fast biopsies.

          -  Primary tumor ≥2 cm acc. to clinical measurement or manifestation of an inflammatory
             breast cancer.

          -  No systemic metastasis, exclusion by chest x-ray, sonogram of the upper abdomen and
             skeletal scintiscan.

          -  Age ≥18 years and ≤65 years.

          -  ECOG < 2/WHO 0-1

          -  Adequate organ function defined as SGOT and bilirubin ≤ 1.5× upper limit WBC ≥ 3000
             /µL Neutrophils ≥ 1000 /µL Platelets ≥ 100,000 /µL Serum creatinine < 2.0 mg/dL

          -  Unremarkable heart echo

          -  No florid hepatitis

          -  Written consent to participate in the treatment optimization protocol

        Exclusion Criteria:

          -  Multicentricity in various quadrants (contact the study office)

          -  Known allergy to E. coli-produced medication

          -  Known allergy to medication containing cremophor (e.g., cyclosporin A)

          -  Patients receiving immunosuppressant therapy

          -  Lack of consent after informing the patient

          -  Lack of willingness to keep and disclose personal medical data as part of the study

          -  Pregnancy, nursing

          -  Secondary malignancy, excluding basalioma of the skin or carcinoma in situ of the
             cervix that has received curative therapy

          -  Pre-existing treatment-resistant cardiac disease, coronary heart disease, arrhythmias,
             cardiac insufficiency

          -  Patients with uncontrolled hypertension (diastolic >95 mmHg)

          -  A history of convulsions

          -  Known hypersensitivity to darbepoetin alfa or any of its other ingredients or a known
             hypersensitivity to r-HuEPO
Clinical trial NCT00081796 (phase 3, status: completed)
Conditions: breast cancer, metastases
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: larotaxel (rpr109881, xrp9881), capecitabine
SMILES: CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@H]3[C@]4(C[C@H]4C[C@H]4OC[C@@]34OC(C)=O)C1=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Eligibility Criteria

        In order to be eligible for this trial you must:

          -  Have a diagnosis of breast cancer that is now metastatic (meaning the cancer has
             spread beyond its original location) or a recurrence of the cancer in its original
             location that cannot be removed by surgery.

          -  Have received previous treatment with anthracyclines (e.g., adriamycin, Doxorubicin)
             and taxanes (e.g., paclitaxel, docetaxel, Taxol®, Taxotere®) for your breast cancer
             and your doctor has determined that these treatment are no longer of benefit to you.

          -  Be at least 18 years of age.

          -  Not be taking other treatments for your cancer at the time you enter this trial.

          -  Not be pregnant.

        Additionally, there are other criteria for study entry that a doctor participating in this
        study will need to review in detail with you and clinical assessments may need to be
        performed (e.g., lab tests, CT scans).
Clinical trial NCT00393718 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: liraglutide, glibenclamide, placebo, placebo
SMILES: CN(C)C(=N)NC(N)=N, COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Diet/exercise therapy with or without an oral anti-diabetic drug for at least eight
             weeks

          -  HbA1c greater than or equal to 7.0% and less than 10.0%

          -  BMI (Body Mass Index) less than 35 kg/m2

        Exclusion Criteria:

          -  Treatment with insulin within the last 12 weeks

          -  Treatment with any drug that could interfere with the glucose level

          -  Any serious medical condition

          -  Females who are pregnant, have intention of becoming pregnant or are breastfeeding
Clinical trial NCT00057616 (phase 3, status: completed)
Conditions: melanoma, neoplasm metastasis
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cc-5013
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        -  Understand and voluntarily sign an informed consent form

          -  Able to adhere to the study visit schedule and other protocol requirements

          -  Metastatic malignant melanoma now stage IV, relapsed or refractory to standard
             metastatic therapy

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             within 7 days of starting study drug

          -  Patients with active brain disease, or newly diagnosed brain metastases, within 4
             weeks prior to the start of study treatment are excluded.
Clinical trial NCT00320268 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: quetiapine fumarate
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has a documented clinical diagnosis of Major Depressive Disorder.

          -  Be able to understand and comply with the requirements of the study.

          -  Able to understand and provide written informed consent

        Exclusion Criteria:

          -  Patients (female) must not be pregnant or lactating

          -  Current or past diagnosis of stroke or transient ischemic attack (TIA).
Clinical trial NCT01715298 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: nva237, placebo
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria: 1. Patients with stable, symptomatic Chronic Obstructive Pulmonary
        Disease (COPD) with airflow obstruction of level 2 and 3 according to the current Global
        initiative for chronic Obstructive Lung Disease (GOLD) strategy (2011). 2. Patients with
        Forced Expiratory Volume in one second (FEV1) ≥ 30% and <80 % of the predicted normal, and
        FEV1/FVC < 0.70 when measured 45 min after the inhalation of 84 µg ipratropium bromide.

        3. Current or ex-smokers with at least 10 cigarette pack years smoking history.

        Exclusion criteria:

          1. Patients with a history of long QT syndrome, with a prolonged QTc measured during
             screening, or patients who have a clinically significant ECG abnormality at screening.

          2. History of malignancy of any organ system (other than localized basal cell carcinoma
             of the skin), treated or untreated, within the past 5 years, regardless of whether
             there is evidence of local recurrence or metastases.

          3. Pregnant or nursing (lactating) women. Women of childbearing potential unless using an
             effective method of contraception.

          4. Patients who in the judgment of the investigator, would be at potential risk if
             enrolled into the study.

          5. Patients who have a clinically significant concomitant disease at screening, including
             but not limited to clinically significant laboratory abnormalities, clinically
             significant renal, cardiovascular, neurological, endocrine, immunological,
             psychiatric, gastrointestinal, hepatic, or hematological abnormalities, or with
             uncontrolled diabetes, which could interfere with the assessment of the efficacy and
             safety of the study treatment.

          6. Patients with a body mass index (BMI) of more than 40 kg/m2.

          7. Patients contraindicated for treatment with, or having a history of reactions/
             hypersensitivity to anticholinergic agents, long and short acting beta-2 agonists, or
             sympathomimetic amines.

          8. Patients with any history of asthma, with onset of symptoms prior to age 40 years, or
             patients with a high blood eosinophil count during screening.

        Other protocol-defnied inclusion/exclusion criteria may apply.
Clinical trial NCT00652002 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol, budesonide, formoterol
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  At least 12 years of age

          -  Diagnosis of asthma

          -  Baseline lung function test results as determined by protocol and required and
             received treatment with inhaled corticosteroids and/or lung treatments specified in
             protocol within the timeframe and doses specified in the protocol

        Exclusion Criteria:

          -  Has required treatment with non-inhaled corticosteroids within previous 4 weeks, has
             sensitivity to drugs specified in the protocol or requires treatment with
             beta-blockers

          -  Had cancer within previous 5 years or currently has any other significant disease or
             disorder as judged by the investigator
Clinical trial NCT00652925 (phase 3, status: completed)
Conditions: arthritis, juvenile rheumatoid
ICD codes: M08.08, M08.48, M08.011, M08.012, M08.019, M08.021, M08.022
Drugs: celecoxib, celecoxib, naproxen
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
Eligibility criteria:

        Inclusion Criteria:

        2-18 years old with active JRA

        Exclusion Criteria:

        other experimental meds, recent changes in arthritis meds
Clinical trial NCT01433393 (phase 3, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: tak-875, tak-875, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. The participant is an outpatient.

          2. The participant signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

        Exclusion Criteria:

          1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or
             any serious pancreatic or hematological disease.

          2. The participant is considered ineligible for the study for any other reason by the
             investigator or sub-investigator.